RituximabSerum sickness following off-label use: 5 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1776卷 / 1期

关键词：

D O I：

10.1007/s40278-019-70556-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：398 / 398

相关论文

共 50 条

[1] RituximabSerum sickness following off label use: case report
Reactions Weekly, 2018, 1699 (1) : 262 - 262
[2] RituximabSerum sickness following an off-label use of rituximab for autoimmune haemolytic anaemia: case report
Reactions Weekly, 2018, 1733 (1) : 288 - 288
[3] ImatinibVarious toxicities following off-label use: 5 case reports
Reactions Weekly, 2021, 1876 (1) : 164 - 164
[4] UstekinumabVarious toxicities following off-label use: 5 case reports
Reactions Weekly, 2019, 1774 (1) : 300 - 300
[5] TemozolomideThrombocytopenia and neutropenia following off-label use: 5 case reports
Reactions Weekly, 2020, 1786 (1) : 154 - 154
[6] RituximabVarious toxicities following off-label use: 5 case reports
Reactions Weekly, 2019, 1734 (1) : 437 - 437
[7] ApremilastVarious toxicities following an off-label use: 5 case reports
Reactions Weekly, 2019, 1784 (1) : 47 - 47
[8] RuxolitinibVarious toxicities following off-label use: 5 case reports
Reactions Weekly, 2023, 1965 (1) : 433 - 433
[9] BevacizumabVarious toxicities following off-label use of bevacizumab: 5 case reports
Reactions Weekly, 2023, 1981 (1) : 90 - 90
[10] Bevacizumab/thalidomideVarious toxicities following off-label use: 5 case reports
Reactions Weekly, 2019, 1745 (1) : 78 - 78

← 1 2 3 4 5 →